MK-677

Key Research Papers and Clinical Trials

The research on MK-677 (ibutamoren) spans several areas, with recent publications focusing primarily on safety concerns and detection methods rather than therapeutic efficacy.

Safety and Adverse Events

Recent case reports have highlighted significant safety concerns with MK-677 use. A 2025 case report documented hepatotoxicity (liver damage) associated with MK-677 use, while a 2024 case study reported reversible gynecomastia (breast tissue enlargement) and hypogonadism (reduced hormone production) in a user of commercial performance-enhancing supplements containing MK-677. Another concerning 2026 case report described spontaneous splenic rupture in a patient who had recently used performance-enhancing compounds, though the direct causal relationship to MK-677 specifically was not established.

A 2022 case report examined the effects of combined LGD-4033 and MK-677 use on body composition and hormonal markers, providing detailed analysis of how these compounds impact skeletal muscle and circulating biomarkers, though this involved concurrent use of multiple substances.

Detection and Analytical Methods

Several studies have focused on developing detection methods for MK-677 in biological samples. A 2023 study established methods for detecting MK-677 in equine hair samples following oral administration, while 2022 research characterized the compound and its metabolites in thoroughbred horses for anti-doping purposes. A 2026 study examined minimal detectable doses in hair testing, using MK-677 as a case example for interpreting hair test results.

Clinical Trials

The clinical trial database shows several completed and ongoing studies:

• A Phase 2 completed trial (NCT00116129) examined MK-677's efficacy and safety for fibromyalgia treatment
• A completed Phase 2 study (NCT05364684) investigated its impact on nonalcoholic fatty liver disease
• A completed Phase 2 trial (NCT00074529) studied MK-677 for Alzheimer's disease treatment
• A completed study (NCT00395291) examined its effects on IGF-1 levels in end-stage renal disease patients
• A currently recruiting Phase 3 study (NCT06948214) is testing LUM-201 (which may be related to growth hormone secretagogue research) in children with growth hormone deficiency

Research Limitations

The available evidence consists primarily of case reports, detection studies, and limited clinical trial information without detailed results. Most recent publications focus on adverse events rather than therapeutic benefits, and sample sizes for individual studies are generally small. The clinical trials listed do not provide outcome data in the available evidence.

This synthesis is based solely on the provided research abstracts and trial listings. Individual medical decisions should always be made in consultation with qualified healthcare providers.